Medix Products begins Phase III of obesity candidate

Medix Products S.A. de C.V. (Mexico City, Mexico) began a Phase III trial of tesofensine (NS2330) to treat obesity. The double-blind, placebo-controlled, Mexican trial will evaluate once-daily 0.25 and 0.5 mg doses of tesofensine for 24 weeks in up to 372 ambulatory adults. Medix Products expects to complete the trial by 2019.

The primary endpoint will test absolute and percent change in body weight. Secondary endpoints will measure the proportion of patients achieving weight loss of >5% and >10%, metabolic and glycemic endpoints, quality of life (QOL) and safety...